WallStSmart
PASG

Passage Bio Inc

NASDAQ: PASG · HEALTHCARE · BIOTECHNOLOGY

$4.40
+0.50% today

Updated 2026-06-04

Market cap
$17.87M
P/E ratio
P/S ratio
EPS (TTM)
$-11.84
Dividend yield
52W range
$4 – $20
Volume
0.1M

Passage Bio Inc (PASG) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20182019202020212022202320242025
Operating cash flow$-18.57M$-39.90M$-80.52M$-126.88M$-118.21M$-78.26M$-47.96M$-31.51M
Capital expenditures$2.54M$1.69M$1.65M$25.64M$5.27M$146000.00$34000.00$0.00
Depreciation
Stock-based comp$1.45M$14.58M$32.69M$18.95M$10.92M$5.82M$3.00M
Free cash flow$-21.11M$-41.59M$-82.17M$-152.52M$-123.48M$-78.41M$-47.99M$-31.51M
Investing cash flow
Financing cash flow
Dividends paid
Share repurchases
Debt repayment
Net change in cash$-23.87M$-6.04M$-94.36M

Frequently asked questions

How much free cash flow does PASG generate?

PASG produced $-31.51M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is PASG's balance sheet healthy?

PASG holds $46.30M in cash and equivalents against — in long-term debt, on $18.75M of shareholder equity. That debt is best read against the cash flow the business throws off each year.